Publication:
Monoclonal antibodies: A review of therapeutic applications and future prospects

Simple item page
dc.Chemicals/CASabciximab, 143653-53-6; adalimumab, 331731-18-1; alemtuzumab, 216503-57-0; alirocumab, 1245916-14-6; bevacizumab, 216974-75-3; daclizumab, 152923-56-3; evolocumab, 1256937-27-5; infliximab, 170277-31-3; OKT 3, 140608-64-6; omalizumab, 242138-07-4; ranibizumab, 347396-82-1; rituximab, 174722-31-7; single chain fragment variable antibody, 334577-34-3, 334577-38-7
dc.FundingDetailsUniversiti Putra Malaysia
dc.FundingDetailsThis work was supported by Universiti Putra Malaysia, Malaysia.
dc.Tradenamesadalimumab; daclizumab; humira; infliximab; muromonab; omalizumab; orthoclone; pg 16; pg 9; ranibizumab; raxibazumab; vrc 01
dc.citedby6
dc.contributor.affiliationsFaculty of Medicine and Health Sciences
dc.contributor.affiliationsUniversiti Putra Malaysia (UPM)
dc.contributor.affiliationsUsmanu Danfodiyo University
dc.contributor.affiliationsUniversity of Thi-Qar
dc.contributor.affiliationsUniversity of Anbar
dc.contributor.affiliationsUniversiti Sains Islam Malaysia (USIM)
dc.contributor.authorMahmuda A.
dc.contributor.authorBande F.
dc.contributor.authorAl-Zihiry K.J.K.
dc.contributor.authorAbdulhaleem N.
dc.contributor.authorMajid R.A.
dc.contributor.authorHamat R.A.
dc.contributor.authorAbdullah W.O.
dc.contributor.authorUnyah Z.
dc.date.accessioned2024-05-28T08:24:58Z
dc.date.available2024-05-28T08:24:58Z
dc.date.issued2017
dc.description.abstractThe increasing demand for monoclonal antibodies (mAbs) used for diagnostic and therapeutic applications has led to the development of large scale manufacturing processes, with improvements in production achieved through continuous optimization of the inherent systems. The number of monoclonal antibodies (mAbs) that have already been approved for therapeutic applications and for use in clinical trials have significantly increased in the past few years. In view of the side effects and limitations of mAbs, several improvements and modifications to monoclonal antibodies have been developed. These modifications have facilitated the use of mAbs in various forms of therapeutic applications such as treatment of infectious diseases caused by bacterial, viral, fungal and parasitic organisms. Monoclonal antibodies have also been applied in the treatment of non-infectious diseases such as cancer, immune diseases, arthritis and other disorders resulting from organ transplantation. This review highlights mAbs applications in biomedicine, and discusses state-of-the-art technologies related to their potential uses. � Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved.
dc.description.natureFinal
dc.identifier.doi10.4314/tjpr.v16i3.29
dc.identifier.epage722
dc.identifier.issn1596-5996
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85017009246
dc.identifier.scopusWOS:000399247000029
dc.identifier.spage713
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85017009246&doi=10.4314%2ftjpr.v16i3.29&partnerID=40&md5=2b9e9df7a3b640385b69679ec0682954
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/8590
dc.identifier.volume16
dc.languageEnglish
dc.language.isoen_US
dc.publisherPharmacotherapy Group
dc.relation.ispartofTropical Journal Of Pharmaceutical Research
dc.sourceScopus
dc.subjectAuto-immune diseases
dc.subjectCancer
dc.subjectInfectious diseases
dc.subjectMetabolic disorders
dc.subjectMonoclonal antibodies
dc.subjectTherapeutic application
dc.titleMonoclonal antibodies: A review of therapeutic applications and future prospects
dc.title.alternativeTrop. J. Pharm. Res.
dc.typeReview
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Monoclonal antibodies A review of therapeutic applications and future prospects.pdf
Size:
205.04 KB
Format:
Adobe Portable Document Format
Download

Collections

Scopus